Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer

NCT03197467 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Pembrolizumab

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]